New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control
Recruiting now
This study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 adults whose cancer returned after platinum therapy will be randomly assigned to the combo …
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC